CA2186595A1 - Immunogenes a base de peptide synthetique pour le traitement de l'allergie - Google Patents

Immunogenes a base de peptide synthetique pour le traitement de l'allergie

Info

Publication number
CA2186595A1
CA2186595A1 CA002186595A CA2186595A CA2186595A1 CA 2186595 A1 CA2186595 A1 CA 2186595A1 CA 002186595 A CA002186595 A CA 002186595A CA 2186595 A CA2186595 A CA 2186595A CA 2186595 A1 CA2186595 A1 CA 2186595A1
Authority
CA
Canada
Prior art keywords
gly
lys
phe
val
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002186595A
Other languages
English (en)
Inventor
Chang Yi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2186595A1 publication Critical patent/CA2186595A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé permettant d'induire la production, chez les mammifères en bonne santé dont les humains, des anticorps à titre élevé dirigés contre un site effecteur dans une chaîne lourde d'IgE humain, tel qu'un site dans le domaine CH4 de la chaîne ?, au moyen de compositions d'immunogènes de peptide synthétique sous une forme multimère ramifiée radialement (telle que des peptides octamères ou hexadécamères) ou monomère disposée linéairement, pour inhiber l'activation des mastocytes et réduire la production d'IgE induite par un allergène. L'invention porte également sur l'utilisation de ces immunogènes de conception optimale relatifs à la chaîne ? d'IgE et exempts de protéines porteuses en tant que composants déterminants dans un vaccin synthétique destiné à produire une immunothérapie pour le traitement de l'allergie. Les peptides selon l'invention contiennent des séquences de stimulation immunitaire contenant un déterminant antigénique du lymphocyte T auxiliaire intégré lié en tandem dans un sens spécifique, pour faciliter la stimulation de la réponse immunitaire dirigée contre le domaine CH4 d'IgE.
CA002186595A 1994-03-28 1995-03-24 Immunogenes a base de peptide synthetique pour le traitement de l'allergie Abandoned CA2186595A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21846194A 1994-03-28 1994-03-28
US08/218,461 1994-03-28
US32891294A 1994-10-25 1994-10-25
US08/328,912 1994-10-25

Publications (1)

Publication Number Publication Date
CA2186595A1 true CA2186595A1 (fr) 1995-10-05

Family

ID=26912926

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002186595A Abandoned CA2186595A1 (fr) 1994-03-28 1995-03-24 Immunogenes a base de peptide synthetique pour le traitement de l'allergie

Country Status (6)

Country Link
EP (1) EP0811016A1 (fr)
JP (1) JPH09510975A (fr)
CN (1) CN1146772A (fr)
AU (1) AU2195395A (fr)
CA (1) CA2186595A1 (fr)
WO (1) WO1995026365A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
CA2245497C (fr) 1996-03-01 2009-02-24 Novartis Ag Immunogenes peptidiques utilises comme vaccins et agents therapeutiques contre les allergies
GB9611673D0 (en) * 1996-06-05 1996-08-07 Peptide Therapeutics Ltd Meningococcal vaccine
EP1037663A2 (fr) 1997-12-16 2000-09-27 Regents Of The University Of Minnesota Procedes permettant de traiter des reponses immunitaires indesirables
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
HUP0200958A3 (en) 1999-04-23 2004-11-29 Pharmexa As Method for down-regulating il5 activity
GB9913327D0 (en) * 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
CA2403739A1 (fr) * 2000-03-15 2001-09-20 Heska Corporation Modele tridimensionnel d'un complexe entre une chaine alpha du recepteur fc-epsilon et une region fc d'un anticorps ige et leurs utilisations
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
IL154219A0 (en) * 2000-09-06 2003-07-31 Pharmexa As Method for down-regulating ige
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
WO2003015716A2 (fr) 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Vaccins d'immunoglobuline e et leurs procedes d'utilisation
IL158287A0 (en) * 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
WO2009023816A1 (fr) * 2007-08-15 2009-02-19 Emory University Procédés de préparation d'anticorps monoclonaux utilisant la technologie du transfert adoptif d'épitope de peptide de fusion (f-peat)
CA2717930A1 (fr) * 2008-03-13 2009-09-17 Yossef Kliger Nouveaux peptides derives de gp96
WO2013083254A1 (fr) 2011-12-09 2013-06-13 Bavarian Nordic A/S Vecteur de poxvirus pour l'expression d'antigènes bactériens liés au fragment c de la toxine tétanique
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
EP2862873B1 (fr) * 2012-06-18 2020-04-29 Nippon Zenyaku Kogyo Co., Ltd. VACCIN À BASE DE PEPTIDE D'IMMUNOGLOBULINE E (IgE)
EP2790442A1 (fr) 2013-04-09 2014-10-15 Alcatel Lucent Système de commande, appareil, procédés et support de stockage lisible par ordinateur stockant des instructions pour un n'ud de réseau et/ou un contrôleur de réseau
CN112237638B (zh) * 2020-10-28 2022-11-29 西安华牧生物科技有限责任公司 降低放射性核素肾浓聚的组合探针及其制备方法
CN114949176A (zh) * 2022-04-11 2022-08-30 中国科学院海洋研究所 一种迟缓爱德华氏菌TraT蛋白的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8913737D0 (en) * 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
WO1994025060A1 (fr) * 1993-04-27 1994-11-10 Ladd Anna E Peptides immunogenes de la lhrh et stimulators d'immunite universelle de synthese pour vaccins
GB9320897D0 (en) * 1993-10-11 1993-12-01 Peptide Therapeutics Ltd Compounds useful in anti-allergy treatment
GB9417086D0 (en) * 1994-08-24 1994-10-12 Peptide Therapeutrics Limited Screen for potential therapeutic compounds

Also Published As

Publication number Publication date
AU2195395A (en) 1995-10-17
EP0811016A1 (fr) 1997-12-10
EP0811016A4 (fr) 1997-12-10
JPH09510975A (ja) 1997-11-04
WO1995026365A1 (fr) 1995-10-05
CN1146772A (zh) 1997-04-02

Similar Documents

Publication Publication Date Title
CA2186595A1 (fr) Immunogenes a base de peptide synthetique pour le traitement de l'allergie
JP4031201B2 (ja) アレルギー治療用免疫原としてのペプチド組成物
Kaumaya et al. Peptide vaccines incorporating a ‘promiscuous’ T‐cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity
ES2346116T3 (es) Epitopos artificiales de celulas t ayudadoras como estimuladores inmunes para peptidos sinteticos inmunogenos.
AU4012095A (en) Synthetic ige membrane anchor peptide immunogens for the treatment of allergy
US6780969B2 (en) Synthetic peptide composition as immunogens for prevention of urinary tract infection
IE911527A1 (en) Improved vaccine compositions
AU2002214938B2 (en) Method for obtaining antigenic structures enhancing specific cross reactivity
CA2457111A1 (fr) Vaccin
US20030170229A1 (en) Vaccine
HK1036804B (en) Peptide composition as immunogen for the treatment of allergy
MXPA00011938A (en) Peptide composition as immunogen for the treatment of allergy
Wang B cell & T cell epitope orientation and adjuvant-free immunization in synthetic vaccine design
HK1143950B (en) Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens
HK1056825A (en) Method for obtaining antigenic structures enhancing specific cross reactivity
HK1037860B (en) Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens

Legal Events

Date Code Title Description
FZDE Dead